易瑞生物实控人拟减持 上市当年净利最高近2年扣非亏

Core Viewpoint - The announcement details the planned share reduction by the controlling shareholder and actual controller of Yirui Biological, which is not expected to significantly impact the company's governance structure or control [1][2]. Group 1: Share Reduction Plan - Yirui (Hainan) Venture Capital Co., Ltd., the controlling shareholder, plans to reduce its holdings by up to 3,531,208 shares, representing 0.88% of the total share capital [1]. - The actual controller, Zhu Hai, intends to reduce his holdings by up to 7,521,390 shares, accounting for 1.87% of the total share capital [1]. - The total planned reduction by both parties does not exceed 3% of the company's total share capital, with specific limits on the number of shares that can be sold within a 90-day period [1]. Group 2: Company Background and Financials - Yirui Biological was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on February 9, 2021, with an initial issuance of 40.86 million shares at a price of 5.31 yuan per share, raising a total of 217 million yuan [2]. - The company has raised a total of 545 million yuan from two fundraising events, with the first round netting 175 million yuan after expenses [3][4]. - The net profit attributable to shareholders for the years 2021, 2022, 2023, and 2024 were 236.51 million yuan, 82.97 million yuan, -184.91 million yuan, and 17.12 million yuan, respectively [4][5]. Group 3: Financial Performance - In 2024, the company's operating revenue is projected to be 224.25 million yuan, a decrease of 11.75% from 2023 [5]. - The net profit attributable to shareholders is expected to increase by 109.26% in 2024, reaching 17.12 million yuan, compared to a loss of 184.91 million yuan in 2023 [5]. - The cash flow from operating activities showed a significant improvement, with a net cash flow of 34.26 million yuan in 2024, compared to a negative cash flow of -37.25 million yuan in 2023, marking a 191.97% increase [5].